Gabriel Clemente de Brito Pereira

Mr. Gabriel Clemente de Brito Pereira


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DGDaniel da Motta Girardi
Daniel da Motta Girardi
LSLara P. Sousa
Lara P. Sousa
TMThiago A. Miranda
Thiago A. Miranda
FHFernanda das Neves Carneiro Haum
Fernanda das Neves Carneiro Haum
GPGabriel Clemente de Brito Pereira
Gabriel Clemente de Brito Pereira
Allan PereiraAllan Pereira
Allan Pereira
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of liver dysfunction or tumor extent. Sorafenib was the first tyrosine kinase inhibitor that improved the overall survival of patients who failed to respond to local therapies or had advanced disease, and for many years, it was the only treatment approved for the first-line setting. However, in recent years, trials have demonstrated an improvement in survival with treatments based on immunotherapy and new targeting agents, thereby extending the treatment options. A phase III trial showed that a combination of immunotherapy and targeted therapy, including atezolizumab plus bevacizumab, improved survival in the first-line setting, and is now considered the new standard of care. Other agents and combinations are being tested, including the combination of nivolumab plus ipilimumab and tremelimumab plus durvalumab, and they reportedly have clinical benefits. The aim of this manuscript is to review the latest approved therapeutic options in first- and second-line settings for advanced HCC and discuss future perspectives.

3 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DGDaniel Girardi
Daniel Girardi
MLMariana A. de Lima
Mariana A. de Lima
GPGabriel Clemente de Brito Pereira
Gabriel Clemente de Brito Pereira
MNMarcelo V. Negrão
Marcelo V. Negrão
RLRossana V. M. López
Rossana V. M. López
PHPaulo Marcelo G. Hoff
Paulo Marcelo G. Hoff
Treatment of localized gastric cancer (LGC) consists of surgical resection followed by adjuvant treatment. Both chemoradiation (CRT) and chemotherapy (CT) regimens have shown benefit in survival outcomes versus observation. However, there are few data comparing these approaches. This study included consecutive patients with LGC treated at Instituto do Cancer do Estado de Sao Paulo (ICESP) from 2012 to 2015. CRT was based on the INT-0116 regimen and CT consisted of a platinum and fluoropyrimidine doublet. Treatment choice was based on physician preference. Toxicity was evaluated for every cycle. Overall survival (OS) analysis was performed by Kaplan-Meier. A propensity score-matched analysis was performed to minimize selection bias. A total of 309 patients were evaluated, 227 in CRT group and 82 in CT group. The most prevalent grade 3/4 toxicities in CRT and CT groups were: nausea/vomiting (9.25 vs 4.9%), fatigue (9.3% vs 2.4%), mucositis (4.4% vs 1.2%), neutropenia (37.8% vs 20.9%), febrile neutropenia (3.9% vs 0%), anemia (4.3% vs 6.1%), thrombocytopenia (2.6% vs 4.9%), neuropathy (0 vs 2.4%) and hand-foot syndrome (0.4% vs 2.4%). Two grade 5 toxicities (febrile neutropenia and anemia) occurred in CRT group. There was no difference in the pattern of recurrence. After a median follow-up of 23.5 months (CRT) and 20.6 months (CT), there was no difference in OS between groups. CT and CRT present similar efficacy and tolerability as adjuvant treatment for LGC.

1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
SSSaulo Brito Silva
Saulo Brito Silva
RBRafael Balsini Barreto
Rafael Balsini Barreto
FOFernanda Cristina Gonçalves de Oliveira
Fernanda Cristina Gonçalves de Oliveira
GMGabriela Schmidt Defende Martin
Gabriela Schmidt Defende Martin
OTOfelia Maria Yukie Takiguchi
Ofelia Maria Yukie Takiguchi
FPFernanda Peria
Fernanda Peria
PURPOSE: Patients with brain metastases are often referred for brain radiotherapy (BrRT) when exclusive palliative management would be more appropriate. To assess the indication of BrRT during end-of-life (EOL) care and evaluate the characteristics of the patients who underwent the treatment. METHODS: This retrospective study comprised patients from four independent oncology centers who had undergone BrRT for metastases. The variables included were Karnofsky performance status (KPS), primary tumor site, metastatic status, neurologic symptomatic status, the number and size of metastases, posterior fossa or meningeal involvement, type of BrRT, having undergone brain metastasectomy, and the availability of systemic therapies after BrRT. Patients were allocated into three subgroups with ≤30, 31-60, and 61-90 days of survival, and a control group of patients who survived >90 days. RESULTS: A total of 546 patients were included in the study. A KPS of <70 ( P = .021), the number of brain metastases ( P = .001), the lack of brain metastasectomy ( P = .006), and the lack of systemic therapies after BrRT ( P = .047) were significantly associated with the EOL subgroups. Multivariate analysis showed that a KPS of <70 ( P < .001), the lack of brain metastasectomy ( P = .015), and the lack of systemic therapies after BrRT ( P = .027) were significantly associated with worse survival. In all, 241 (44.1%) patients died within 90 days—120 (22.0%) within 30 days, 75 (13.7%) within 31-60 days, and 46 (8.4%) within 61-90 days of BrRT. Patients with colorectal cancer were significantly more likely to die within 90 days of BrRT than >90 days. CONCLUSION: Considering patients' performance status and whether they are candidates for brain metastasectomy or systemic therapies after BrRT is critical to improving BrRT benefits in scenarios of EOL.